Boehringer Ingelheim has announced plans to start phase III trials of its second-generation drug BIBW 2992(i) in lung cancer patients.
So far, BIBW 2992(i) has been shown to particularly affect lung cancer patients with specific genetic mutations.
In a phase I study evaluating the activity of BIBW 2992(i) in patients with various solid tumours, encouraging results were obtained in patients with nonsmall-cell lung cancer (NSCLC).
Details of this stage in the clinical development of the treatment are being finalised with both the FDA and the EMEA.
The German-based company said the move demonstrates its commitment to the discovery and development of novel compounds in oncology.
Dr Andreas Barner, vice-chairman of the board of managing directors at Boehringer Ingelheim, said: “We are using advances and breakthrough science to actively develop targeted therapies – biologicals and small molecules – in areas of unmet medical need, with a particular interest in lung cancer.
“With the progress made we have again underlined our commitment to discovering and developing innovative cancer treatments that provide high therapeutic value for patients, physicians and healthcare providers.”
Copyright © PA Business 2007